UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 9, 16, 2022

REDHAWK HOLDINGS CORP.

(Exact name of registrant as specified in its charter)

Nevada	000-54323	20-3866475
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
100 Petroleum Drive, Suite 200, Lafayette, Louisiana 70508
100 Petroleum Drive Suite 200, Lafayette, Louisiana 70508
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (337) 269-5933

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 78.01 ~~Regulation~~Other ~~FD Disclosure~~Events

The Registrant ~~providing~~confirmed ~~herein~~today that it is in discussions with a leading healthcare provider (“Provider”) of pharmaceutical care and clinical services in the United States with the mutual objective (i) to reach an ~~abbreviated~~agreement ~~investor~~to install the Registrant’s SANDD ~~update~~Pro™ ~~related~~needle incineration devices in each of the Provider’s pharmacies and clinics in order to ~~its~~reduce ~~financial~~the Provider’s needle disposal costs and ~~operational~~eliminate ~~outlook.~~incidents ~~The~~of ~~abbreviated~~workplace ~~investor~~needle ~~update~~stick isinjuries; ~~furnished~~and ~~herein~~(ii) asto ~~Exhibit~~reach 99an agreement for the Provider to offer to the public in each of its pharmacies the over-the-counter “white label” sale of the Registrant’s SANDD mini™.1.

In accordance with General Instruction B.2 of Form 8-K, the information under this Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Other Exhibits

Exhibit 99.1 Abbreviated Investor Update dated May 9, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.

	REDHAWK HOLDINGS CORP.
Date: May 11, 2022	By:	/s/ G. Darcy Klug
Date: May 16, 2022	By:	/s/ G. Darcy Klug
		G. Darcy Klug
		Chief Financial Officer

Filing Compare · RedHawk Holdings Corp.